Weight loss injections, particularly glucagon-like peptide 1 (GLP-1) analogs such as semaglutide and tirzepatide, are revolutionizing the treatment of obesity. Known as “incretin mimetics,” these medications have garnered attention for their remarkable effectiveness in facilitating weight loss. As their popularity grows, a critical question arises: Could these medications replace obesity surgery altogether? This question touches on a broader […]